Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1-rearranged soft-tissue sarcoma cell model.

The Journal of pathology - 1 Jun 2024

Chen Yanjiang, Steiner Sabrina, Hagedorn Catherine, Kollar Sarah, Pliego-Mendieta Alicia, Haberecker Martina, Plock Jan, Britschgi Christian, Planas-Paz Lara, Pauli Chantal

Abstract excerpt

Genomic rearrangements of the neurotrophic receptor tyrosine kinase genes (NTRK1, NTRK2, and NTRK3) are the most common mechanism of oncogenic activation for this family of receptors, resulting in sustained cancer cell proliferation. Several targeted therapies have been approved for tumours harbouring NTRK fusions and a new generation of TRK inhibitors has already been developed due to acquired resistance. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Indazoles
Share to Neurofibromin 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pyridones

Share to Pyrimidinones

Share to Receptor, trkA

Share to Sarcoma

Share to Sirolimus

Share to Soft Tissue Neoplasms

Source

Identifiers

PMID: 38613194
DOI: 10.1002/path.6282

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1-rearranged soft-tissue sarcoma cell model.PMID 38613194Read ↗

TRKing down drug resistance in NTRK fusion-positive cancers†.Semantic proximity Read ↗

Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.Semantic proximity Read ↗

Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery Protocol.Semantic proximity Read ↗

NTRK1-3 Fusions in Sarcomas: Prevalence, Significance, and Clinical Implications – A Systematic ReviewSemantic proximity Read ↗

TRKing down an old oncogene in a new era of targeted therapy.Semantic proximity Read ↗

Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomasSemantic proximity Read ↗

Integrative Proteogenomic and Single-Cell Analysis Reveals RTK Switching and Metabolic Reprogramming as Synthetic Lethal Vulnerabilities in FGFR Inhibitor ResistanceSemantic proximity Read ↗

ERK signaling promotes resistance to TRK kinase inhibition in NTRK fusion-driven glioma mouse modelsSemantic proximity Read ↗

YAP signaling promotes resistance to MEK and AKT inhibition in <i>NF1</i> -related MPNSTsSemantic proximity Read ↗

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.Semantic proximity Read ↗

Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapySemantic proximity Read ↗

Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.